Helen Beard
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Helen Beard has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Kim M. Hemsley
Flinders University
3 shared publications - Nazzmer Nazri
School of Medicine, College of Health, Adelaide University, Adelaide, SA, Australia
2 shared publications A. Pas
New Zealand Centre for Conservation Medicine, Auckland Zoo, Auckland, New Zealand
1 shared publication- Andrew P. Shoubridge
Microbiome and Host Health Programme, South Australian Health and Medical Research Institute (SAHMRI), Adelaide, South Australia, Australia
1 shared publication - Barbara King
Women’s and Children’s Hospital
1 shared publication G. Greaves
Department of Conservation, Wellington, New Zealand
1 shared publication
Latest Publications
- Open Access
- 30 March 2023
- Published by Taylor & Francis in New Zealand Veterinary Journal
- Vol. 71 (4) , 186-193
A lower motor neuron disease in takahē (Porphyrio hochstetteri) is an endoplasmic reticulum storage disease
To investigate the pathogenesis of a disease in takahē with intracytoplasmic inclusion bodies in lower motor neurons.Four cases aged between 5 and 12 years, from three different wildlife sanctuarie...
- 30 March 2023
- Published by Taylor & Francis in New Zealand Veterinary Journal
- Vol. 71 (4) , 186-193
Open AccessA lower motor neuron disease in takahē (Porphyrio hochstetteri) is an endoplasmic reticulum storage disease
To investigate the pathogenesis of a disease in takahē with intracytoplasmic inclusion bodies in lower motor neurons.Four cases aged between 5 and 12 years, from three different wildlife sanctuarie...
- 8 February 2023
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 138 (2) , 59
A prohibitin-targeting drug modifies aspects of disease in a mouse model of Sanfilippo syndrome
- 8 February 2023
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 138 (2) , 59
A prohibitin-targeting drug modifies aspects of disease in a mouse model of Sanfilippo syndrome
- 9 January 2021
- Published by Wiley in Journal of Inherited Metabolic Disease
- Vol. 44 (3) , 763-776
Is SGSH heterozygosity a risk factor for early‐onset neurodegenerative disease?
Lysosomal dysfunction may be an important factor in the pathogenesis of neurodegenerative disorders such as Parkinson's disease (PD). Heterozygous mutations in the gene encoding the lysosomal enzyme glucocerebrosidase (GBA1) have been found in PD patients, and some but not all mutations in other lysosomal enzyme genes, for example, NPC1 and MCOLN1 have been associated with PD. We have examined the behaviour and brain structure of mice carrying a D31N mutation in the sulphamidase (Sgsh) gene which encodes a lysosomal sulphatase. Female heterozygotes and wildtype mice aged 12‐, 15‐, 18‐ and 21‐months of age underwent motor phenotyping and the brain was comprehensively evaluated for disease‐associated lesions. Heterozygous mice exhibited impaired performance in the negative geotaxis test when compared with wildtype mice. Whilst the brain of Sgsh heterozygotes aged up to 21‐months did not exhibit any of the gross features of PD, Alzheimer's disease or the neurodegenerative lysosomal storage disorders, for example, loss of striatal dopamine, reduced GBA activity, α‐synuclein‐positive inclusions, perturbation of lipid synthesis, or cerebellar Purkinje cell drop‐out, we noted discrete structural aberrations in the dendritic tree of cortical pyramidal neurons in 21‐month old animals. The overt disease lesions and resultant phenotypic changes previously described in individuals with heterozygous mutations in lysosomal enzyme genes such as glucocerebrosidase may be enzyme dependent. By better understanding why deficiency in, or mutant forms of some but not all lysosomal proteins leads to heightened risk or earlier onset of classical neurodegenerative disorders, novel disease‐causing mechanisms may be identified.
- 9 January 2021
- Published by Wiley in Journal of Inherited Metabolic Disease
- Vol. 44 (3) , 763-776
Is SGSH heterozygosity a risk factor for early‐onset neurodegenerative disease?
Lysosomal dysfunction may be an important factor in the pathogenesis of neurodegenerative disorders such as Parkinson's disease (PD). Heterozygous mutations in the gene encoding the lysosomal enzyme glucocerebrosidase (GBA1) have been found in PD patients, and some but not all mutations in other lysosomal enzyme genes, for example, NPC1 and MCOLN1 have been associated with PD. We have examined the behaviour and brain structure of mice carrying a D31N mutation in the sulphamidase (Sgsh) gene which encodes a lysosomal sulphatase. Female heterozygotes and wildtype mice aged 12‐, 15‐, 18‐ and 21‐months of age underwent motor phenotyping and the brain was comprehensively evaluated for disease‐associated lesions. Heterozygous mice exhibited impaired performance in the negative geotaxis test when compared with wildtype mice. Whilst the brain of Sgsh heterozygotes aged up to 21‐months did not exhibit any of the gross features of PD, Alzheimer's disease or the neurodegenerative lysosomal storage disorders, for example, loss of striatal dopamine, reduced GBA activity, α‐synuclein‐positive inclusions, perturbation of lipid synthesis, or cerebellar Purkinje cell drop‐out, we noted discrete structural aberrations in the dendritic tree of cortical pyramidal neurons in 21‐month old animals. The overt disease lesions and resultant phenotypic changes previously described in individuals with heterozygous mutations in lysosomal enzyme genes such as glucocerebrosidase may be enzyme dependent. By better understanding why deficiency in, or mutant forms of some but not all lysosomal proteins leads to heightened risk or earlier onset of classical neurodegenerative disorders, novel disease‐causing mechanisms may be identified.